Findings

What do systematic reviews say?

46 questions · 48 findings · 7 reviews · Hypertension

No studies found 1 · 2.1%GRADE not reported 0 · 0%Very low 2 · 4.2%Low 14 · 29.2%Moderate 27 · 56.3%High 4 · 8.3%

Congestive heart failure · patients with hypertension

CCBs probably leads to higher congestive heart failure compared with diuretic (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.37 [1.25, 1.51]
5 studies · 34072 participants
Moderate

Cardiovascular mortality · patients with hypertension

CCBs showed no clear difference in cardiovascular mortality compared with diuretic (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.02 [0.93, 1.12]
4 studies · 32721 participants
Moderate

All‐cause mortality · patients with hypertension

CCBs showed no clear difference in all‐cause mortality compared with β‐blocker (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.94 [0.88, 1]
4 studies · 44825 participants
Moderate

Myocardial infarction · patients with hypertension

CCBs showed no clear difference in myocardial infarction compared with β‐blocker (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.9 [0.79, 1.02]
3 studies · 22249 participants
Moderate

Stroke · patients with hypertension

CCBs probably leads to lower stroke compared with β‐blocker (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.77 [0.67, 0.88]
3 studies · 22249 participants
Moderate

Congestive heart failure · patients with hypertension

CCBs showed no clear difference in congestive heart failure compared with β‐blocker (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.83 [0.67, 1.04]
2 studies · 19915 participants
Low